Loading…
The study results were published in the peer-reviewed journal eBioMedicine.
Intensity Therapeutics, Inc. (Nasdaq: INTS) announced the publication of clinical data showing an 11.9-month overall survival (OS) for its investigational cancer therapy INT230-6. The results were detailed in an article published in the peer-reviewed journal eBioMedicine.
The reported 11.9-month OS is a key metric from the study, highlighting the potential efficacy of INT230-6 in treating certain types of cancer. The company did not provide a direct comparator for this survival data.
As of the latest available data, Intensity Therapeutics has a free float of 54,806,000 shares and 60,065,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.